(Q41271555)

29 September 2017

1 reference

title

A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy (English)

1 reference

29 September 2017

0 references

R Abraham

1

1 reference

29 September 2017

R L Basser

series ordinal

2

1 reference

29 September 2017

M D Green

series ordinal

3

1 reference

29 September 2017

publication date

1 December 1996

1 reference

29 September 2017

1 reference

29 September 2017

volume

15

1 reference

29 September 2017

issue

6

1 reference

29 September 2017

page(s)

406-429

1 reference

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma

29 September 2017

cites work

1 reference

12 December 2020

Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial

1 reference

12 December 2020

Dose-response in the treatment of breast cancer: a critical review

1 reference

12 December 2020

High-dose chemotherapy for breast cancer

1 reference

12 December 2020

Dose optimization of anthracyclines

1 reference

12 December 2020

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

12 December 2020

A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin

1 reference

12 December 2020

Adriamycin (NSC-123,127): a new antibiotic with antitumor activity

1 reference

12 December 2020

Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy

1 reference

12 December 2020

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

12 December 2020

Doxorubicin cardiotoxicity: analysis of prevailing hypotheses

1 reference

12 December 2020

Risk factors for doxorubicin-induced congestive heart failure

1 reference

12 December 2020

Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index

1 reference

12 December 2020

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

1 reference

12 December 2020

Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collab

1 reference

12 December 2020

Serial studies of cardiac function in patients receiving adriamycin

1 reference

12 December 2020

Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results

1 reference

12 December 2020

Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters

1 reference

12 December 2020

Chemotherapy for invasive thymoma. A 13-year experience

1 reference

12 December 2020

Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes

1 reference

12 December 2020

The anthracycline antineoplastic drugs

1 reference

12 December 2020

Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies?

1 reference

12 December 2020

Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer

1 reference

12 December 2020

Monitoring for anthracycline cardiotoxicity.

1 reference

12 December 2020

Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity

1 reference

12 December 2020

The cardiotoxicity of adriamycin and daunomycin in children

1 reference

12 December 2020

Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP

1 reference

12 December 2020

Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia

1 reference

12 December 2020

Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia

1 reference

12 December 2020

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

12 December 2020

Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study

1 reference

12 December 2020

Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia

1 reference

12 December 2020

CAF in metastatic breast cancer: standard therapy or another effective regimen?

1 reference

12 December 2020

New anthracycline antitumor antibiotics

1 reference

12 December 2020

Pharmacokinetics and metabolism of anthracyclines

1 reference

12 December 2020

High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team

1 reference

12 December 2020

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

12 December 2020

Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin

1 reference

12 December 2020

Salvage therapy for soft tissue sarcomas

1 reference

12 December 2020

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer

1 reference

12 December 2020

The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

1 reference

12 December 2020

Chemotherapy of advanced gastric cancer: present status, future prospects

1 reference

12 December 2020

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

1 reference

12 December 2020

Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.

1 reference

12 December 2020

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

12 December 2020

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

1 reference

12 December 2020

Dose-intensive chemotherapy with cytokine support.

1 reference

12 December 2020

Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B

1 reference

12 December 2020

Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma

1 reference

12 December 2020

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer

1 reference

12 December 2020

Chemotherapy of non-Hodgkin's aggressive lymphomas.

1 reference

12 December 2020

Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases

1 reference

12 December 2020

How to improve cytotoxic therapy in advanced breast cancer.

1 reference

12 December 2020

Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

12 December 2020

Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer

1 reference

12 December 2020

A NEW ANTIBIOTIC WITH CYTOSTATIC PROPERTIES: RUBIDOMYCIN

1 reference

12 December 2020

Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances

1 reference

12 December 2020

Present status of anthracyclines in the adjuvant treatment of breast cancer.

1 reference

12 December 2020

Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma

1 reference

12 December 2020

Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation

1 reference

12 December 2020

Amputation and adriamycin in primary osteosarcoma: a 5-year report

1 reference

12 December 2020

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia

1 reference

12 December 2020

Strategies for prevention of anthracycline cardiotoxicity

1 reference

12 December 2020

Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer

1 reference

12 December 2020

Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study

1 reference

12 December 2020

Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity

1 reference

12 December 2020

Comparative mammalian metabolism of adriamycin and daunorubicin

1 reference

12 December 2020

High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer

1 reference

12 December 2020

Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association

1 reference

12 December 2020

New anthracycline derivatives: What for?

1 reference

12 December 2020

Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity

1 reference

12 December 2020

Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group

1 reference

12 December 2020

Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide

1 reference

12 December 2020

Anthracyclines and the heart

1 reference

12 December 2020

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

12 December 2020

A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia

1 reference

12 December 2020

Chemotherapy of adult acute lymphoblastic leukaemia

1 reference

12 December 2020

Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial

1 reference

12 December 2020

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis

1 reference

12 December 2020

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

12 December 2020

In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex

1 reference

12 December 2020

Myocarditis associated with doxorubicin cardiotoxicity

1 reference

12 December 2020

Infusional anthracyclines: is slower better? If so, why?

1 reference

12 December 2020

Early anthracycline cardiotoxicity

1 reference

12 December 2020

Activity and safety of epirubicin plus paclitaxel in advanced breast cancer

1 reference

12 December 2020

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

12 December 2020

Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic fromS. Peucetius var.caesius

1 reference

12 December 2020

Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines

1 reference

12 December 2020

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin

1 reference

12 December 2020

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma

1 reference

12 December 2020

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

1 reference

12 December 2020

The use of combination chemotherapy in the treatment of early stage Hodgkin's disease.

1 reference

12 December 2020

Epirubicin high-dose therapy in advanced breast cancer: preliminary clinical data. Epirubicin as a single agent in breast cancer

1 reference

12 December 2020

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer

1 reference

12 December 2020

Stereochemistry of Intercalation: Interaction of Daunomycin with DNA

1 reference

12 December 2020

Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex

1 reference

12 December 2020

Doxorubicin hydrochloride (Adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography

1 reference

12 December 2020

Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer

1 reference

12 December 2020

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens

1 reference

12 December 2020

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

1 reference

12 December 2020

Mitoxantrone: an overview of safety and toxicity

1 reference

12 December 2020

Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer

1 reference

12 December 2020

Ten-year results of the treatment of primary operable breast carcinoma: A summary of 304 patients evaluated by the TNM system

1 reference

12 December 2020

Current status of ALL/AUL therapy in adults

1 reference

12 December 2020

Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells

1 reference

12 December 2020

Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy

1 reference

12 December 2020

Impact of doxorubicin on survival in advanced ovarian cancer

1 reference

12 December 2020

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

12 December 2020

Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia

1 reference

12 December 2020

Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy: A southwest oncology group study

1 reference

12 December 2020

Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer

1 reference

12 December 2020

New cytotoxic drugs in treatment of breast cancer

1 reference

12 December 2020

Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma

1 reference

12 December 2020

Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial

1 reference

12 December 2020

Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study

1 reference

12 December 2020

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

1 reference

12 December 2020

Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer

1 reference

12 December 2020

A clinicopathologic analysis of adriamycin cardiotoxicity

1 reference

12 December 2020

Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: clinical results

1 reference

12 December 2020

VP-16 and cisplatin as first-line therapy for small-cell lung cancer

1 reference

12 December 2020

Clinical pharmacology of 4-demethoxydaunorubicin (DMDR)

1 reference

12 December 2020

Systemic Therapy of Advanced Breast Cancer

1 reference

12 December 2020

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1 reference

12 December 2020

Efficacy of intensive, high-dose anthracycline-based therapy in intermediate- and high-grade non-Hodgkin's lymphomas.

1 reference

12 December 2020

The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane

1 reference

12 December 2020

DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA

1 reference

12 December 2020

Therapy of small cell lung cancer: a perspective on two decades of clinical research

1 reference

12 December 2020

VAD chemotherapy for refractory multiple myeloma

1 reference

12 December 2020

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

1 reference

12 December 2020

Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy

1 reference

12 December 2020

Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma

1 reference

12 December 2020

Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma.A southwest oncology group study

1 reference

12 December 2020

Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P388 cells.

1 reference

12 December 2020

Anthracyclines: cardiotoxicity and its prevention

1 reference

12 December 2020

Role of iron in adriamycin biochemistry

1 reference

12 December 2020

Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline

1 reference

12 December 2020

Early and delayed clinical cardiotoxicity of doxorubicin

1 reference

12 December 2020

Morpholinyl anthracyclines: option for reversal of anthracycline resistance

1 reference

12 December 2020

Dose: a critical factor in cancer chemotherapy

1 reference

12 December 2020

Metabolism of 4'-modified analogs of doxorubicin. unique glucuronidation pathway for 4'-epidoxorubicin

1 reference

12 December 2020

Late cardiac effects of adjuvant therapy: too soon to tell?

1 reference

12 December 2020

Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial

1 reference

12 December 2020

Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy

1 reference

12 December 2020

A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy

1 reference

12 December 2020

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

12 December 2020

Does more intensive treatment cure more patients with acute myeloid leukemia? The BGMT Group

1 reference

12 December 2020

Combination chemotherapy with Taxol (paclitaxel) in metastatic breast cancer

1 reference

12 December 2020

The effect of treatment in fractionated schedules with the combination of X-irradiation and six cytotoxic drugs on the RIF-1 tumor and normal mouse skin.

1 reference

12 December 2020

A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B study

1 reference

12 December 2020

Survival of hematopoietic and leukemic colony-forming cells in vivo following the administration of daunorubicin or adriamycin

1 reference

12 December 2020

The anthracyclines: will we ever find a better doxorubicin?

1 reference

12 December 2020

Acute promyelocytic leukemia with t(15;17) following inhibition of DNA topoisomerase II

1 reference

12 December 2020

A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast

1 reference

12 December 2020

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

12 December 2020

Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes

1 reference

12 December 2020

Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule

1 reference

12 December 2020

1 reference

12 December 2020

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

1 reference

12 December 2020

4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data

1 reference

12 December 2020

Etoposide and split-dose cisplatin in small-cell lung cancer.

1 reference

12 December 2020

Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal tim

1 reference

12 December 2020

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience

1 reference

12 December 2020

Doxorubicin-cyclophosphamide: effective chemotherapy for advanced endometrial adenocarcinoma.

1 reference

12 December 2020

Chemotherapy of advanced soft-tissue sarcomas in adults

1 reference

12 December 2020

Prevention of the Cardiotoxic Effects of Adriamycin and Daunomycin in the Isolated Dog Heart

1 reference

12 December 2020

Binding of adriamycin-Fe3+ complex to membrane phospholipids

1 reference

12 December 2020

Preliminary pharmacokinetic model for adriamycin (NSC-123127)

1 reference

12 December 2020

Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer

1 reference

12 December 2020

Adriamycin. A new anticancer drug with significant clinical activity

1 reference

12 December 2020

Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial

1 reference

12 December 2020

A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer

1 reference

12 December 2020

10.2165/00002018-199615060-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

29 September 2017

1035258277

0 references

1 reference